



## PRESS RELEASE

# Biocartis to participate in key investor conferences in November 2015

**Mechelen, Belgium, 3 November 2015:** Biocartis (Euronext Brussels: **BCART**), an innovative molecular diagnostics company, today announced that its Chief Executive Officer Rudi Pauwels, Deputy CEO & Managing Director Hilde Windels and Chief Financial Officer Ewoud Welten, will be participating in key investor conferences in November 2015:

- **4<sup>th</sup> Annual KBC Securities Benelux Biotech & Healthcare Conference**
  - Attendees Biocartis: Rudi Pauwels and Ewoud Welten
  - Date: November 10, 2015
  - Venue: New York City (USA)
- **Canaccord Genuity Medical Technology and Diagnostics Forum**
  - Attendees Biocartis: Rudi Pauwels and Hilde Windels
  - Date: November 19, 2015
  - Venue: New York City (USA)

----- END -----

### For more information:

#### **Renate Degrave (Corporate Communications & Investor Relations)**

+32 15 632 600

[press@biocartis.com](mailto:press@biocartis.com)

#### **Consilium Strategic Communications**

Amber Fennell, Jessica Hodgson, Chris Welsh, Hendrik Thys

+44 (0) 203 709 5701 (London, UK)

[biocartis@consilium-comms.com](mailto:biocartis@consilium-comms.com)

### **About Biocartis**

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis launched the Idylla™ platform commercially in September 2014 together with its first assay to identify BRAF Mutations in metastatic melanoma. Its second assay, a KRAS Mutation panel for colorectal cancer, was launched in June 2015. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Further information can be found at: [www.biocartis.com](http://www.biocartis.com).